A collection of content all about sofosbuvir.

Jul 12, 2020: Sofosbuvir and daclatasvir were linked to faster recovery and improved survival in studies in Iran.

Sep 3, 2020: Rates of liver complications were similar, but HIV-positive people had more non-liver cancers and non-liver-related deaths.

Nov 4, 2013: Sofosbuvir and ribavirin cured between 67 and 88 percent of those coinfected with HIV and genotypes 1, 2 or 3 of hepatitis C virus.

Oct 28, 2019: The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.

Apr 29, 2013: Sofosbuvir and daclatasvir, taken with or without ribavirin, cured 100 percent of previously treated participants of hepatitis C virus in...

Dec 6, 2013: The FDA has approved Sovaldi (sofosbuvir), a once-daily oral nucleotide analog polymerase inhibitor to treat people with hepatitis C.

Feb 12, 2021: Despite limited testing and clinical visits, 95% of the study population was able to achieve a sustained virological response.

Jul 27, 2019: Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.

May 11, 2020: Reyataz is a protease inhibitor HIV Medication. Reyataz was approved by the FDA in 2003.

May 11, 2020: Prezista is a protease inhibitor HIV Medication. Prezista was approved by the FDA in October 2008.

Mar 13, 2013: An all-oral combination therapy of sofosbuvir, ledipasvir and ribavirin boasts a 100 percent cure rate among people with hepatitis C virus.

Oct 15, 2019: The drug can quickly reverse opioid-driven overdoses.

Jul 22, 2019: Pharmacists oversaw the delivery of hepatitis C treatment in a recent study.

Jul 5, 2018: In a recent study, even the presence of viral mutations associated with resistance to treatment did not affect the cure rate.

Oct 10, 2014: The first once-daily fixed-dose combination therapy to treat hep C has hit the scene, with neither interferon nor ribavirin in tow.

Mar 11, 2013: In an interim analysis, simeprevir and sofosbuvir showed high cure rates in those who had failed a hep C therapy and had mild to moderate fibr...

Sep 17, 2012: Gilead Sciences’ experimental NS5B polymerase inhibitor sofosbuvir (GS-7977) rapidly reduced hepatitis C virus (HCV) levels in people coinfect...

Jan 30, 2020:

Mar 16, 2020: Six weeks, compared with the standard 12 weeks, was associated with an unacceptably high rate of viral relapse.